8-K: Profound Medical Reports 82% Revenue Growth in Q1 2025, Driven by TULSA-PRO Adoption

Profound Medical Corp. announced an 82% increase in revenue for the first quarter of 2025, driven by strong adoption of its TULSA-PRO technology.

Summary

• Profound Medical Corp. reported its Q1 2025 financial results, showing significant revenue growth.
• Revenue reached approximately $2.6 million, an 82% increase compared to $1.4 million in Q1 2024.
• Recurring revenue, which includes sales of TULSA-PRO consumables, leases, and services, was $1.8 million.
• One-time sales of capital equipment contributed $820,000 to the total revenue.
• The gross margin improved to 71% from 60% in the prior year period, attributed to higher manufacturing efficiency and increased capital system sales.
• Operating expenses increased to approximately $13.0 million from $8.7 million in the prior year, due to commercial expansion, R&D investments, and conference costs.
• The net loss for Q1 2025 was approximately $10.7 million, or $0.36 per common share, compared to a net loss of $6.6 million, or $0.27 per common share, in Q1 2024.
• As of March 31, 2025, Profound had approximately $46.4 million in cash.
• As of May 8, 2025, there were 30,053,142 common shares issued and outstanding.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth and improved gross margins are positive, the increased net loss and operating expenses temper the overall outlook. The company's future plans and positive study results contribute to a moderately positive sentiment.

Positives

• Significant revenue growth of 82% year-over-year indicates increasing market adoption of TULSA-PRO.
• Improved gross margin of 71% demonstrates enhanced operational efficiency and profitability.
• Positive initial results from the CAPTAIN study support the clinical benefits of TULSA compared to robotic radical prostatectomy.
• The upcoming TULSA-AI module and TULSA+ solution are expected to further drive growth and market penetration.
• Favorable reimbursement codes (Urology APC Level 7) provide a competitive advantage.

Negatives

• The net loss increased to $10.7 million in Q1 2025 from $6.6 million in Q1 2024.
• Operating expenses rose significantly to $13.0 million due to commercial expansion and R&D investments.

Risks

• Increased operating expenses could continue to impact profitability.
• The company's ability to successfully launch and commercialize TULSA-AI and TULSA+ will be critical for future growth.
• Market factors and the company's ability to execute its operational and budget plans could affect financial results.
• Regulatory approvals and reimbursement challenges in the medical device industry could impact the company's performance.

Future Outlook

Profound Medical anticipates continued growth driven by the TULSA-PRO system and plans to launch the TULSA-AI module for BPH and the TULSA+ total interventional-MRI solution in the second half of 2025.

Management Comments

• Arun Menawat, Profound's CEO and Chairman, stated that the revenue growth trajectory was in line with internal expectations and that AUA 2025 was a very successful meeting.
• Menawat highlighted TULSA's precision, flexibility, and economic proposition, noting the favorable Urology APC Level 7 codes.

Industry Context

The announcement highlights Profound Medical's position in the competitive medical device market, particularly in the area of prostate disease treatment. The company's focus on incision-free therapies and AI-enhanced technology aligns with the broader industry trend towards minimally invasive procedures and advanced imaging techniques.

Comparison to Industry Standards

• Profound Medical's TULSA-PRO competes with other prostate cancer treatment options such as robotic radical prostatectomy (RP) and other ablation technologies.
• The CAPTAIN study results suggest that TULSA offers advantages over RP in terms of post-operative experience, including reduced blood loss, shorter hospital stays, and faster recovery.
• The company's Urology APC Level 7 codes provide a reimbursement advantage compared to peers at Level 6, potentially driving adoption in various treatment settings.
• Companies like Intuitive Surgical (da Vinci Surgical System) and EDAP TMS (HIFU technologies) are key competitors in the broader market for minimally invasive surgical and ablation technologies.

Stakeholder Impact

• Shareholders may react positively to the revenue growth but negatively to the increased net loss.
• Customers (physicians and patients) may benefit from the improved clinical outcomes and reimbursement advantages of TULSA-PRO.
• Employees may experience increased workload and opportunities due to the company's expansion.

Next Steps

• Profound Medical plans to roll out its TULSA-AI module for BPH and the TULSA+ total interventional-MRI solution offering in the second half of 2025.
• The company will continue to monitor and report financial results and business updates.

Key Dates

Keywords

TULSA-PRO, Profound Medical, Revenue Growth, Financial Results, Prostate Cancer, BPH, Medical Device, CAPTAIN Study